$MARKSANS Marksans Pharma shares jumped over 11% today

$MARKSANS Marksans Pharma shares jumped over 11% today after reporting stellar Q1 FY27 results — profit nearly tripled to ₹157 crore, revenue rose 36% YoY, and EBITDA margin expanded sharply to 25.3%. The company also crossed ₹1,000 crore in cash reserves and strengthened its European presence through acquisitions of QliniQ B.V. (Netherlands) and ABCnow GmbH (Germany). 💰 Q1 FY27 Financial Highlights Metric Q1 FY27 Q1 FY26 YoY Change Revenue from Operations ₹ 840.8 crore ₹ 620 crore +35.6 % EBITDA ₹ 213 crore ₹ 100 crore +112.8 % EBITDA Margin 25.3 % 16.2 % +910 bps PAT (Consolidated) ₹ 157.17 crore ₹ 58.32 crore +169.5 % Cash Balance ₹ 1,058 crore — Record High 🌍 Regional Performance UK & Europe: ₹ 356 crore revenue (+74.7 % YoY) — highest ever; driven by new product launches and market share gains. US & North America: ₹ 377 crore revenue (+15.1 % YoY) — 45 % of total sales; strong order pipeline. Australia & New Zealand: ₹ 88 crore revenue (+53.7 % YoY) — portfolio expansion and new launches. Rest of World: ₹ 20 crore revenue (–36.8 % YoY) — impacted by Middle East shipment delays but sequential improvement. 🧩 Strategic Moves & Acquisitions QliniQ B.V. (Netherlands): Acquired 100 % stake for € 7.5 million. ABCnow GmbH (Germany): Definitive agreement for € 1.1 million purchase. These deals expand Marksans’ footprint in regulated European markets and enhance its product distribution network. 📈 Market Reaction Share Price: Up 11–13 % intraday; trading near ₹ 190 levels. Volume Spike: Heavy delivery buying after results announcement. Analyst Sentiment: Angel One: “Strong profitability and cash position support long‑term growth.” CNBC TV18: “Record EBITDA and margin expansion signal robust execution.” 🔮 Outlook & Risks Positive Drivers Sustained growth in regulated markets (UK, US, EU). Integration of QliniQ and ABCnow to boost European revenues. Strong cash reserves → capacity for organic and inorganic expansion.